Dechert LLP‘s Boston-based patent prosecution team is well-known for its capabilities in all patent prosecution matters as well as in portfolio management for its clients. The team’s workload includes advising on IP due diligence and negotiations, and on the sale and acquisition of patent portfolios. The cases are often of considerable value and vary between domestic and international in scope. The life sciences industry is the team’s key focus area and it also has an increasing focus on biologics. The team heads Andrea Reid and Andrew Wilkins are described as being ’very experienced, engaged and responsive lead partners’, with key attorney to note in the team being Chad Davis.
Legal 500 redaktioneller Kommentar
- Profil
- Soziale Medien
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘Very experienced, engaged, and responsive lead partners.'
Kernmandanten
- 4E Therapeutics
- Aer Therapeutics
- Agenus
- Akamis Bio
- Aldeyra Therapeutics
- Atlas Ventures
- Arcutis
- argenx SE
- AVEO Oncology / AVEO Pharmaceutical
- Bayer Healthcare
Highlight-Mandate
- Handled the patent strategy work on behalf of Nimbus Therapeutics’ highly selective, allosteric TYK2 inhibitor portfolio to address multiple immune-mediated diseases, which was acquired by Takeda in December 2022 for $6bn.
- Advised Chiesi Farmaceutici S.p.A. on IP analysis in its $1.48bn all-cash transaction to acquire Amryt Pharma Plc.
- Handled the patent strategy and IP diligence on behalf of argenx SE on its transcontinental share offering raising $1.1bn in new funds.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Praxisleitung
Andrea Reid; Andrew Wilkins
Weitere Kernanwält*innen
Chad Davis